Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Rev. méd. Chile ; 144(9): 1226-1229, set. 2016. ilus
Artículo en Español | LILACS | ID: biblio-830633

RESUMEN

Neuromyelitis optica (NMO) is a severe demyelinating disease of the central nervous system, which preferentially attacks the optic nerve and spinal cord. It is associated with antibodies against aquaporin 4. Morbidity and mortality are higher than in multiple sclerosis and its treatment focuses on immunosuppressive drugs. Immunomodulators are contraindicated. We report a previously healthy 35-year-old man, presenting with NMO concomitantly with systemic lupus erythematosus. His evolution was torpid with three outbreaks in the 10 months after the diagnosis, requiring a first-line therapy with methylprednisolone and cyclophosphamide and then a second-line therapy with rituximab.


Asunto(s)
Humanos , Masculino , Adulto , Neuromielitis Óptica/complicaciones , Lupus Eritematoso Sistémico/complicaciones , Paresia/complicaciones , Paresia/tratamiento farmacológico , Espasmo/complicaciones , Espasmo/tratamiento farmacológico , Metilprednisolona/uso terapéutico , Neuromielitis Óptica/tratamiento farmacológico , Antirreumáticos/uso terapéutico , Ciclofosfamida/uso terapéutico , Rituximab/uso terapéutico , Glucocorticoides/uso terapéutico , Lupus Eritematoso Sistémico/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA